Expertise in
12
conditions

Liora Harel

Petah Tiqwa, M, IL 
Clinical Trials:Currently Recruiting for 3 Trials
Expertise in
12
conditions
Petah Tiqwa, M, IL 

Overview

Liora Harel practices in Petah Tiqwa, Israel. Ms. Harel is highly rated in 12 conditions, according to our data. Her top areas of expertise are Scleroderma, Systemic Sclerosis (SSc), Rheumatic Fever, and Juvenile Idiopathic Arthritis (JIA).

Her clinical research consists of co-authoring 60 peer reviewed articles and participating in 4 clinical trials. MediFind looks at clinical research from the past 15 years.

Gender

Female

Locations

Petah Tiqwa, M, Israel
Other Locations
Tel Aviv, TA, Israel
Ramat Aviv, TA, Israel
59 Tshernichovski Street, Kfar Saba, M 44281, Israel
Et Taiyiba, M, Israel
Petach Tikvah, Israel

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

4 Clinical Trials

A Phase 3 Multicenter Study to Evaluate the Long-Term Safety and Efficacy of Baricitinib in Patients From 1 Year to <18 Years of Age With Juvenile Idiopathic Arthritis (JIA)
A Phase 3 Multicenter Study to Evaluate the Long-Term Safety and Efficacy of Baricitinib in Patients From 1 Year to <18 Years of Age With Juvenile Idiopathic Arthritis (JIA)
Enrollment Status: Recruiting
Publish Date: February 10, 2026
Intervention Type: Drug
Study Drug: Baricitnib
Study Phase: Phase 3
Open-Label, Randomized Study With a Tocilizumab Reference Arm to Evaluate Safety, Efficacy and Pharmacokinetics of Baricitinib in Children From 1 to Less Than 18 Years of Age With Systemic Juvenile Idiopathic Arthritis.
Open-Label, Randomized Study With a Tocilizumab Reference Arm to Evaluate Safety, Efficacy and Pharmacokinetics of Baricitinib in Children From 1 to Less Than 18 Years of Age With Systemic Juvenile Idiopathic Arthritis.
Enrollment Status: Recruiting
Publish Date: February 10, 2026
Intervention Type: Drug
Study Drug: Baricitinib
Study Phase: Phase 3
Observational Study of Pediatric Rheumatic Diseases: The CARRA Registry
Observational Study of Pediatric Rheumatic Diseases: The CARRA Registry
Enrollment Status: Recruiting
Publish Date: October 14, 2025
A Randomized, Double-Blind, Placebo-Controlled, Withdrawal, Safety and Efficacy Study of Oral Baricitinib in Patients From 2 Years to Less Than 18 Years Old With Juvenile Idiopathic Arthritis (JIA)
A Randomized, Double-Blind, Placebo-Controlled, Withdrawal, Safety and Efficacy Study of Oral Baricitinib in Patients From 2 Years to Less Than 18 Years Old With Juvenile Idiopathic Arthritis (JIA)
Enrollment Status: Completed
Publish Date: October 07, 2022
Intervention Type: Drug
Study Drug: Baricitnib
Study Phase: Phase 3
View 1 Less Clinical Trial

60 Total Publications

The Natural History of DADA2 Vasculitis in a Large Cohort and Factors Associated with Disease-Related Damage.
The Natural History of DADA2 Vasculitis in a Large Cohort and Factors Associated with Disease-Related Damage.
Journal: The Journal of rheumatology
Published: January 15, 2026

Frequently Asked Questions about Liora Harel

Is Liora Harel a top-rated expert for Scleroderma?

MediFind is an objective health platform that identifies experts based on real-world data. Liora Harel is classified as an Distinguished expert for Scleroderma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Liora Harel participate in research or clinical trials?

Yes. Liora Harel has published 60 articles and abstracts on conditions like Scleroderma. You can view a list of Liora Harel's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Harel's expertise for a condition
ConditionClose
    View All 8 Distinguished Conditions
    View All 32 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile